Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    at-101 sclc
Show Display Options
Rank Status Study
1 Recruiting Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Drug: topotecan hydrochloride;   Drug: cyclodextrin-based polymer-camptothecin CRLX101
2 Completed Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Interventions: Drug: AT-101;   Drug: topotecan
3 Completed
Has Results
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Drug: R-(-)-gossypol acetic acid;   Other: pharmacological study;   Other: laboratory biomarker analysis
4 Completed R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: R-(-)-gossypol acetic acid;   Drug: cisplatin;   Drug: etoposide
5 Active, not recruiting An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Conditions: Brain Metastases;   Lung Cancer;   Breast Cancer;   Melanoma;   Malignant Glioma
Interventions: Drug: 2B3-101;   Drug: Trastuzumab;   Drug: 2B3-101 60 mg/m2 every 4 weeks;   Drug: 2B3-101 50 mg/m2 every 3 weeks
6 Recruiting Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Conditions: Ovarian Cancer;   Adverse Effects
Intervention: Drug: Sunitinib

Indicates status has not been verified in more than two years